Identifying safety problems in the General Practice - Analysis of the treatment process of oral anticoagulation therapy;Analyse des behandlungsprozesses bei der oralen antikoagulationstherapie zur identifikation von sicherheitsproblemen in der hausärztlichen versorgung

Zeitschrift fur Allgemeinmedizin

Volumn 85, Issue 4, 2009, Pages 148-155

  Saal, Kristina ^a   Hoffmann, Barbara ^a   Blauth, Eckart ^a   Rohe, Julia ^a,b   Beyer, Martin ^a   Harder, Sebastian ^c   Gerlach, Ferdinand Michael ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Arztliches Zentrum fur Qualitat in der Medizin   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Anticoagulants; Drug monitoring; Family practice; Safety management

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; DRUG CONTRAINDICATION; DRUG SAFETY; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MEDICAL DOCUMENTATION; MEDICATION ERROR; PATIENT MONITORING; PATIENT SAFETY;

EID: 77249134107     PISSN: 09376801     EISSN: 14399229     Source Type: Journal    
DOI: 10.3238/zfa.2009.0148     Document Type: Article

References (35)

1. Avery AJ, Sheikh A, Hurwitz B et al. Safer medicines management in primary care. Br J GP 2002; 52, S17-S22
2. Miller GC, Britt HC, Valenti L. Adverse drug events in general practice patients in Australia. MJA 2006; 184: 321-324
3. Thomson LA, Winterstein AG, Søndergaard B, Haugbølle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 2007; 41: 1141-26
4. National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) http://www.nccmerp.org/aboutMedErrors.html (letzter Zugriff 23.6.2008)
5. Avery AJ, Sheikh A, Hurwitz B et al. Safer medicines management in primary care. Br J GP 2002; 52, S17-S22
6. Gurwitz JH, Field TS, Harrold LR et al. Incidence and preventability of adverse drug events among older person in the ambulatory setting. Journal of the American Medical Association 2003; 289: 1107-1116
7. Howard RL, Avery AJ, Slavenburg S, Roayl S, Pipe G, Lucassen P, Pirmohamed M. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 007; 63: 136-47
8. Schwabe UH, Paffrath DH. Arzneiverordnungs-Report 2006. Springer Medizin Verlag, Heidelberg 2007
9. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296: 1858-1866
10. Howard RL, Avery AJ, Slavenburg S et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007; 63: 136-47
11. Runciman WB, Roughead EE, Semple SJ, Adams RJ. Adverse drug events and medication errors in Australia. Int J Qual Health Care 2003; 15: i49-i59
12. Institute for Safe Medication Practices: ISMP's List of High-Alert Medications. http://www.ismp.org/Tools/highalertmedications.pdf (letzter Zugriff 5.6.2008)
13. Feldstein AC, Smith DH, Perrin N et al. Reducing Warfarin Medication Inter-actions. An interrupted time series evaluation. Arch Intern Med 2006; 166: 1009-1015
14. Claes N, Buntinx F, Vijgen J et al. The Belgian Improvement Study on Oral Anticoagulation Therapy: a randomized clinical trial, European Heart Journal 26:2159-2165
15. Scottish Intercollegiate Guidelines Network. Chapter 13 Oral Anticoagulants in SIGN Publication No. 36 Antithrombotic Therapy. ISBN 1899893 76 8. Published March 1999, Last modified December 2001. http://www.sign.ac.uk/ guidelines/fulltext/36/section13.html (23.06.08) (SIGN)
16. Institute for Clinical Systems Improvement. Health Care Guidelines. Anti-coagulation Therapy Supplement. Third Edition November 2003. http://www.icsi.org/guidelines-and-more/g1-os-prot/cardiovascular/ anti-thrombotic-therapy-supplement-guideline-14045/antithrombotic-therapy- supplement-guideline.html (16.03.05) (ICSI)
17. British Columbia Health Services. Guidelines and Protocols Advisory Committee. Initiation and Maintenance of Warfarin Therapy. Victoria, Canada. January 2004. (BCHealthServices) http://www.healthservices.gov.bc.ca/msp/ protoguides/gps/warfarin-therapy.pdf (23.6.2008)
18. Rote Liste® online. Editio Cantor Verlag, Aulendorf 2004. http://www.roteliste.de/Online/index-html (23.6.2008)
19. www.scholz-datenbank.de/title/title.asp
20. Micromedix Healthcare Series. Thomson Micromedix, Greenwood Village, Colorado, USA
21. Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: impact of a new algorithm on risk determination, Clin Pharmacol Ther. 2004; 76: 85-96
22. Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Soc Geriatr 2007; 55(S2): S373-S382
23. Pape A, Tebbenjohaanns J. Antikoagulation bei Vorhofflimmern. Intensivmed 2005; 42: 74-78
24. Rottlaender D, Scherner M, Schneider T, Erdmann E. Multimedikation, Compliance und Zusatzmedikation bei Patienten mit kardiovaskulären Erkrankungen. Dtsch Med Wochenschr 2007; 132: 139-44
25. Harder S, Saal K, Blauth E, Beyer M, Gerlach FM. Appropriateness and surveillance of medication in a cohort of diabetic patients on polypharmacy. Int J Clin Pharm Ther (in press)
26. Koerner T, Beyer M, Tayar D, Gerlach FM, Szecsenyi J. The EQuiP Electronic Medical Record Audit Tool (EMRAT) in a German morbidity registration project (Abstract). European Journal of General Practice 2004; 10: 175-176
27. Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvularatrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 2007; 23: 83-91
28. Sandars J, Esmail A. The frequency and nature of medical error in primary care: understanding the diversity across studies. Fam Pract 2001; 20: 231-236
29. Merlo J, Liedholm H, Lindblad U et al. Precsriptions with potential drug inter-actions dispensed at Swedish pharmacies in January 1999: cross sectional study, BMJ 2001; 232: 427-428
30. Turk A, Sidler P, Bühler H, Christen S. Qualität der oralen Langzeitantikoagulation: eine Beobachtungsstudie. Praxis 2003; 92: 1769-1773
31. Claes N, Buntinx F, Vijgen J et al. The Belgian Improvement Study on Oral Anticoagulation Therapy: a randomized clinical trial, European Heart Journal 26: 2159-2165
32. Bhasale AL, Miller GC, Reid SE, Britt HC. Analysing potential harm in Australian general practices: an incident-monitoring study. MJA 1998; 169: 73-76
33. Hurley JS, Roberts M, Solberg LI et al. Laboratory safety monitoring of chronic medications in ambulatory care settings. J Gen Intern Med 2005; 20: 331-333
34. Leitliniengruppe Hessen, Hausärztliche Leitlinie Antikoagulation unter http://www.leitlinien.de/leitlinienanbieter/deutsch/pdf/ hessenantikoagulation (letzter Zugriff 11.8.08)
35. Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobsen A et al. Delivery of optimized anticoagulant therapy: Consensus statement from the anticoagulation forum. Ann Pharmacother 2008; 42: 979-988